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HAMLET (Human a-lactalbumin made lethal to tumor
cells) is a protein-lipid complex that kills tumor cells and
immature cells but spares healthy, differentiated cells. The
complex is formed from partially unfolded a-lactalbumin
and oleic acid, both of which are abundant constituents of
human milk. The folding change occurs after removal of
Ca2+  from native a-lactalbumin, and the partially
unfolded protein exposes new fatty acid binding domains,
which fit oleic acid. The fatty acid is needed for the tumo-
ricidal activity of the complex, as the unfolded protein
alone does not kill tumor cells.
HAMLET shows broad anti-tumor activity (>40 different
lymphoma and carcinoma cell lines in vitro), suggesting
that very basic cell death pathways are activated in tumor
cells. The mechanism of cell death is complex but our
studies have identified several death pathways activated
by HAMLET in tumor cells, including apoptosis, anoikis
and autophagy. The complex is internalized and causes
rapid mitochondrial destruction. After translocation to
the nuclei, HAMLET impairs the transcriptional machin-
ery by high affinity binding to histones and nucleosomes.
We have compared the transcriptomes of carcinoma cells
and healthy cells of the same tissue origin and the differ-
ences in cellular responses to HAMLET will be discussed.
The resistance of healthy, differentiated cells to HAMLET
is paradoxical, but healthy cells take up little HAMLET,
there is no detectable translocation of HAMLET to the
nuclei or evidence of DNA damage.
New tumour treatments should aim to destroy cancer cells
without harming healthy tissues. Few molecules possess
such selectivity, however, and due to their toxicity, current
cancer therapies often cause severe side effects. In vivo
studies have shown that HAMLET delays the progression
of human brain tumor xenografts in a rat model. HAMLET
was shown to efficiently remove/reduce human skin pap-
illomas in a placebo-controlled clinical study. Finally,
intra-vesical injection of HAMLET killed human bladder
cancer tissue, while sparing surrounding healthy tissue.
HAMLET thus shows great promise as a new anti-cancer
agent. The possible usefulness in breast cancer will be dis-
cussed.
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